0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector

Verify with CMS →

adalimumab-fkjp

RxCUI: 2640404

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
0.3%
Plan Coverage
16
Plans Covering
T2.5
Avg Tier
91.7%
Prior Auth Required

What the CMS Formulary Data Shows for 0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector

Per the CMS 2026 Part D formulary file, 0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector (RxNorm concept RXCUI 2640404, generic name adalimumab-fkjp) appears on 12 distinct formulary files spanning 16 Medicare Part D plan offerings - 0.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 3, with a cross-plan average of Tier 2.5.

Real-world access to 0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector depends on utilization management as much as tier placement: 91.7% of covering formularies require prior authorization. 0% require step therapy. 91.7% apply quantity limits.

Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector today.

Coverage Details

Formularies covering
12
Plans covering
16
Coverage rate
0.3%
Tier range
Tier 1 – Tier 3
Average tier
Tier 3, Preferred Brand

Restrictions

Prior authorization required
91.7% of formularies
Step therapy required
0% of formularies
Quantity limits
91.7% of formularies

Tier Distribution Across Plans

4 plans
Tier 1, Preferred Generic
12 plans
Tier 3, Preferred Brand

Medicare Advantage Plans (MA-PD) Covering 0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector

16 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
SeniorCare Complete (HMO D-SNP) SOUTH COUNTRY HEALTH ALLIANCE T1 Yes $0 MN
AbilityCare (HMO D-SNP) SOUTH COUNTRY HEALTH ALLIANCE T1 Yes $0 MN
Alameda Alliance Wellness (HMO D-SNP) ALAMEDA ALLIANCE FOR HEALTH T1 Yes $0 CA
Community Care's Partnership Program (HMO D-SNP) COMMUNITY CARE HEALTH PLAN, INC. T1 No $0 WI
Troy Medicare (HMO) TROY HEALTH, INC. T3 Yes $0 NC
Troy Medicare for Dual-eligible Beneficiaries (HMO D-SNP) TROY HEALTH, INC. T3 Yes $0 NC
Contra Costa Health Care Plus (HMO D-SNP) CONTRA COSTA COUNTY MEDICAL SERVICE DBA CONTRA COSTA HEALTH T3 Yes $0 CA
Keystone First VIP Choice (HMO D-SNP) VISTA HEALTH PLAN, INC. T3 Yes $0 PA
AmeriHealth Caritas VIP Care (HMO D-SNP) VISTA HEALTH PLAN, INC. T3 Yes $0 PA
First Choice VIP Care (HMO D-SNP) SELECT HEALTH OF SOUTH CAROLINA, INC. T3 Yes $0 SC
AmeriHealth Caritas VIP Care (HMO D-SNP) AmeriHealth Caritas VIP Next, Inc. T3 Yes $0 DE
AmeriHealth Caritas VIP Care Choice (HMO D-SNP) AmeriHealth Caritas VIP Next, Inc. T3 Yes $0 DE
AmeriHealth Caritas VIP Care (HMO D-SNP) AMERIHEALTH CARITAS FLORIDA INC T3 Yes $0 FL
AmeriHealth Caritas VIP Care (HMO D-SNP) AMERIHEALTH CARITAS LOUISIANA, INC. T3 Yes $0 LA
AmeriHealth Caritas VIP Care (HMO D-SNP) AMERIHEALTH CARITAS NORTH CAROLINA, INC. T3 Yes $0 NC
AmeriHealth Caritas VIP Care (HMO D-SNP) AMERIHEALTH MICHIGAN, INC. T3 Yes $0 MI

Frequently Asked Questions

Is 0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector covered by Medicare Part D?

Yes, 0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector is covered by 16 Medicare Part D plans (0.3% of all Part D formularies).

What tier is 0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector on Medicare Part D plans?

0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector averages Tier 2.5 across Part D plans, ranging from Tier 1 to Tier 3.

Does 0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector require prior authorization?

91.7% of Part D formularies require prior authorization for 0.8 ML adalimumab-fkjp 50 MG/ML Auto-Injector. Step therapy: 0%. Quantity limits: 91.7%.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial